



CANCER PREVENTION & RESEARCH INSTITUTE OF TEXAS

Award ID:
CP120036

Project Title:
TexCITE (Texas Cancer ImmunoTherapy Enterprise): Focused
development of innovative cell therapies for cancer

Award Mechanism:
Company Relocation

Principal Investigator:
Sando, Gregg

Entity:
Cell Medica

Lay Summary:

Cell Medica is a leader in the development of cellular immunotherapy for cancer applications. Cell Medica is applying for a Relocation Award to achieve FDA approval for two cell therapies: Cytorex EBV for the treatment of cancers associated with the Epstein Barr virus (EBV) and Cytovir CMV for cytomegalovirus (CMV) infections in patients following bone marrow transplant. Support for Cytorex EBV fits with CPRIT's mission to foster new therapies for cancer treatment. 1) Cellular immunotherapies provide powerful tools for the treatment of cancer and Cytorex EBV is a breakthrough for patients with EBV-associated cancers. 2) The safety of Cytorex EBV will improve long-term outcomes allowing treatment of older patients not suitable for standard regimens. 3) Cell Medica will relocate its headquarters to Texas, creating 20 jobs and also establish a manufacturing and distribution facility. 4) Cell Medica is developing Cytorex EBV with Baylor College of Medicine; a successful collaboration will enhance the research capability of this institution. 5) Clinical trials will include large centers in Texas and maintain these institutions at the leading edge of cancer research. Similarly, the development of Cytovir CMV provides the opportunity for CPRIT to support a new approach to treating viral infections in cancer patients following bone marrow transplant. Cytovir CMV is commercially available in Europe and will likely require an additional clinical trial in the US for FDA approval.